Cargando…

An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide

Understanding, predicting, and minimizing the immunogenicity of peptide-based therapeutics are of paramount importance for ensuring the safety and efficacy of these products. The so-called anti-drug antibodies (ADA) may have various clinical consequences, including but not limited to the alteration...

Descripción completa

Detalles Bibliográficos
Autores principales: Holley, Claire K., Cedrone, Edward, Donohue, Duncan, Neun, Barry W., Verthelyi, Daniela, Pang, Eric S., Dobrovolskaia, Marina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707785/
https://www.ncbi.nlm.nih.gov/pubmed/34946542
http://dx.doi.org/10.3390/molecules26247461
_version_ 1784622522651639808
author Holley, Claire K.
Cedrone, Edward
Donohue, Duncan
Neun, Barry W.
Verthelyi, Daniela
Pang, Eric S.
Dobrovolskaia, Marina A.
author_facet Holley, Claire K.
Cedrone, Edward
Donohue, Duncan
Neun, Barry W.
Verthelyi, Daniela
Pang, Eric S.
Dobrovolskaia, Marina A.
author_sort Holley, Claire K.
collection PubMed
description Understanding, predicting, and minimizing the immunogenicity of peptide-based therapeutics are of paramount importance for ensuring the safety and efficacy of these products. The so-called anti-drug antibodies (ADA) may have various clinical consequences, including but not limited to the alteration in the product’s distribution, biological activity, and clearance profiles. The immunogenicity of biotherapeutics can be influenced by immunostimulation triggered by the presence of innate immune response modulating impurities (IIRMIs) inadvertently introduced during the manufacturing process. Herein, we evaluate the applicability of several in vitro assays (i.e., complement activation, leukocyte proliferation, and cytokine secretion) for the screening of innate immune responses induced by ten common IIRMIs (Bacillus subtilis flagellin, FSL-1, zymosan, ODN2006, poly(I:C) HMW, poly(I:C) LMW, CLO75, MDP, ODN2216, and Escherichia coli O111:B4 LPS), and a model biotherapeutic Forteo™ (teriparatide). Our study identifies cytokine secretion from healthy human donor peripheral blood mononuclear cells (PBMC) as a sensitive method for the in vitro monitoring of innate immune responses to individual IIRMIs and teriparatide (TP). We identify signature cytokines, evaluate both broad and narrow multiplex cytokine panels, and discuss how the assay logistics influence the performance of this in vitro assay.
format Online
Article
Text
id pubmed-8707785
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87077852021-12-25 An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide Holley, Claire K. Cedrone, Edward Donohue, Duncan Neun, Barry W. Verthelyi, Daniela Pang, Eric S. Dobrovolskaia, Marina A. Molecules Article Understanding, predicting, and minimizing the immunogenicity of peptide-based therapeutics are of paramount importance for ensuring the safety and efficacy of these products. The so-called anti-drug antibodies (ADA) may have various clinical consequences, including but not limited to the alteration in the product’s distribution, biological activity, and clearance profiles. The immunogenicity of biotherapeutics can be influenced by immunostimulation triggered by the presence of innate immune response modulating impurities (IIRMIs) inadvertently introduced during the manufacturing process. Herein, we evaluate the applicability of several in vitro assays (i.e., complement activation, leukocyte proliferation, and cytokine secretion) for the screening of innate immune responses induced by ten common IIRMIs (Bacillus subtilis flagellin, FSL-1, zymosan, ODN2006, poly(I:C) HMW, poly(I:C) LMW, CLO75, MDP, ODN2216, and Escherichia coli O111:B4 LPS), and a model biotherapeutic Forteo™ (teriparatide). Our study identifies cytokine secretion from healthy human donor peripheral blood mononuclear cells (PBMC) as a sensitive method for the in vitro monitoring of innate immune responses to individual IIRMIs and teriparatide (TP). We identify signature cytokines, evaluate both broad and narrow multiplex cytokine panels, and discuss how the assay logistics influence the performance of this in vitro assay. MDPI 2021-12-09 /pmc/articles/PMC8707785/ /pubmed/34946542 http://dx.doi.org/10.3390/molecules26247461 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Holley, Claire K.
Cedrone, Edward
Donohue, Duncan
Neun, Barry W.
Verthelyi, Daniela
Pang, Eric S.
Dobrovolskaia, Marina A.
An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide
title An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide
title_full An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide
title_fullStr An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide
title_full_unstemmed An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide
title_short An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide
title_sort in vitro assessment of immunostimulatory responses to ten model innate immune response modulating impurities (iirmis) and peptide drug product, teriparatide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707785/
https://www.ncbi.nlm.nih.gov/pubmed/34946542
http://dx.doi.org/10.3390/molecules26247461
work_keys_str_mv AT holleyclairek aninvitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT cedroneedward aninvitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT donohueduncan aninvitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT neunbarryw aninvitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT verthelyidaniela aninvitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT pangerics aninvitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT dobrovolskaiamarinaa aninvitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT holleyclairek invitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT cedroneedward invitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT donohueduncan invitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT neunbarryw invitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT verthelyidaniela invitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT pangerics invitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide
AT dobrovolskaiamarinaa invitroassessmentofimmunostimulatoryresponsestotenmodelinnateimmuneresponsemodulatingimpuritiesiirmisandpeptidedrugproductteriparatide